{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028143","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.752164+00:00","generated_at":"2026-05-26T17:07:51.490227+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cabaletta Bio: rese-cel shows deepening responses; 3/4 SLE in remission, first LN complete renal response","bullets":["3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all 6 SLE/LN patients off immunosuppressants and steroids.","First dermatomyositis patient maintained major TIS improvement at 3 months off all therapies; IMNM patients showed more gradual improvement.","First SSc patient showed skin improvements and lung function improvement at 3 months post-infusion off disease-specific therapies.","Safety: 90% of first 10 patients had no or Grade 1 CRS; 90% had no ICANS. Deep B cell depletion confirmed via lymph node biopsy.","Enrollment: 50 clinical sites actively recruiting; 26 patients enrolled as of Feb 13, 2025; plan to meet FDA in H1 2025 on registrational design."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028143","json":"https://secwatch.observer/filing/0001193125-25-028143.json","markdown":"https://secwatch.observer/filing/0001193125-25-028143.md","text":"https://secwatch.observer/filing/0001193125-25-028143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525028143/0001193125-25-028143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525028143/d916444d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:07:51.490227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}